Cipla boosts investment in Ethris to advance mRNA therapies in emerging markets
Cipla Limited has announced an additional investment of EUR 3 million in Ethris GmbH, further strengthening its involvement in the mRNA technology sector. This move follows an initial investment of EUR 15 million in 2022 and underscores Cipla’s commitment to advancing mRNA-based treatments, particularly for patients in emerging markets. Ethris, recognized as a leader in […]